Adverse skin reactions secondary to sintilimab for advanced gastric adenocarcinoma: A case report and literature review.

Abstract

Immune checkpoint inhibitors, a class of anticancer drugs, which act via enhancing T cell responses against tumor cells, are associated with immune-related adverse events. The skin is one of the most commonly affected organs. In the present study, a case of a 78-year-old man, who developed systemic eczema dermatitis due to neoadjuvant treatment of locally advanced gastric adenocarcinoma with sintilimab combined with Tigio plus oxaliplatin regimen, was reported. The eczema dermatitis completely subsided after treatment with methylprednisolone. The patient and his family strongly requested surgical intervention. Postoperative pathology revealed a pathological complete response.